---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-26-000046"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2026-07-08T20:13:40+00:00"
generated_at: "2026-07-08T20:14:04.410884+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tarsus acquires iRenix Medical for ~$75M upfront; adds late-stage ocular antiseptic IRX-101

## Summary
- Upfront consideration of $75M: $37.5M cash + $37.5M in Tarsus common stock (607,093 shares).
- Potential approval/commercial milestones up to $490M plus low-to-mid single-digit revenue sharing.
- IRX-101 Phase 2b/3 RELIEF trial: ~50% relative reduction in post-procedural pain (p=0.0003) vs povidone-iodine.
- Phase 3 study expected to start H1 2027 with results in 2028; FDA-aligned program.
- Over 11M intravitreal injections performed annually in US; no new FDA-approved ocular antiseptic in >40 years.

## SEC filing metadata
- accession: 0001819790-26-000046
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2026-07-08T20:13:40+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/0001819790-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/tars-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-26-000046
- JSON: https://secwatch.observer/filing/0001819790-26-000046.json
- Plain text: https://secwatch.observer/filing/0001819790-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.